QURE SEC Filings, Earnings & Splits

uniQure N.V. filed a Form 8-K cover page dated November 4, 2026, with no substantive event details disclosed in the provided text.

uniQure N.V. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, reporting routine financial results and disclosures including share-based compensation, revenue, and debt facility details.

uniQure N.V. filed a Form 8-K cover page with no substantive disclosure of a material event; the filing contains only XBRL cover-page data identifying the registrant and its securities.

A Schedule 13G/A amendment was filed regarding beneficial ownership of uniQure N.V. (QURE) common shares. The filing indicates a change in a previously reported passive ownership position.

uniQure N.V. filed a Form 8-K with the SEC on September 29, 2026, providing standard cover page information and XBRL data. No material event was disclosed beyond the filing itself.

uniQure N.V. announced the submission of a Biologics License Application to the FDA for accelerated approval of ifezuntirgene inilparvovec (AMT-130) for Huntington's disease, and a Marketing Authorisation Application to the UK's MHRA for the same treatment.